Riverain Medical out of Miamisburg, Ohio just announced that it has received European and Canadian approvals for the company’s two software image analysis products designed to assist radiologists with analyzing chest X-rays. OnGuard is a tool for identifying suspicious instances of early stage tumors in the lungs, while SoftView is a separate package that enhances overall x-ray image clarity.
From the press release:
Riverain’s OnGuard Chest X-ray CAD works in conjunction with the reading of standard digital chest X-rays to quickly and comprehensively identify solitary pulmonary nodules that may be early-stage lung cancer. In Europe and Canada, lung cancer is the leading cause of death due to cancer. Lung cancer accounts for 20 percent of all cancer deaths in Europe and 27 percent in Canada.(1) When detected in its earliest stages, the survival rate for lung cancer patients more than triples. Unfortunately, few lung cancers are detected at this early stage.(2)
“Throughout the world, lung cancer continues to kill people at an alarming rate as patients often go undiagnosed with the disease until it has progressed to an advanced stage,” said Diane Hirakawa, Chairman and CEO of Riverain
Medical. “Riverain is excited to provide the clinical community and patients in Europe and Canada with the OnGuard technology, allowing radiologists across the globe to better detect lung cancer at an earlier stage.”
Riverain’s SoftView technology creates an enhanced soft tissue image of the chest by suppressing bone on a standard chest X-ray. SoftView increases image clarity to help radiologists better detect and diagnose medical conditions such as pulmonary nodules, pneumothoraces and improperly placed lines and tubes.
Press release: Riverain Medical Announces International Availability of Its OnGuard Computer-Aided Detection Technology and SoftView Enhanced Chest Imaging Technology …
The OnGuard has received FDA PMA approval in the United States.
Softview product page… SoftView brochure… OnGuard product page… OnGuard brochure…
